This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH

Ticker(s): MRK, UTHR

Who's the expert?

Institution: National Jewish Health

  • Director of clinical cardiology at National Jewish Health, associate professor of clinical practice and the university of Colorado, and fellow of the American college of cardiology.
  • Currently manages ~100 patients with pulmonary arterial hypertension.
  • Research interests include cardiac sarcoid, public health, exercise and health outcomes, and cardiac nutrition.

Interview Questions

How does this data reflect on the likelihood of sotatercept's approval?

Added By: max_admin

How would sotatercept impact the treatment paradigm for PAH?

Added By: max_admin

On a scale of 1-10, how would you rate your excitement for sotatercept?

Added By: max_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.